<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367638</url>
  </required_header>
  <id_info>
    <org_study_id>MG1111_P1</org_study_id>
    <nct_id>NCT02367638</nct_id>
  </id_info>
  <brief_title>Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults</brief_title>
  <official_title>A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether varicella live vaccine is safe and
      effective in the healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the unsolicited adverse events during 42 days after vaccination</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Varicella (Chicken Pox)</condition>
  <arm_group>
    <arm_group_label>MG1111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VARIVAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG1111</intervention_name>
    <description>Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection</description>
    <arm_group_label>MG1111</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX</intervention_name>
    <description>VARIVAX is administered by subcutaneous injection</description>
    <arm_group_label>VARIVAX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female individuals between 20 and 55 years of age at screening test

               -  In the case of female, individuals must be applicable for one of the following;

               -  In the case of female of childbearing potential, any negative pregnancy test
                  using urine hCG at screening

               -  Menopausal for at least 2 years

               -  Surgical sterilization (status after hysterectomy, bilateral oophorectomy,
                  bilateral tubal ligation or the status using other contraceptive methods)

               -  Monogamous relationship with vasectomized partner prior to screening visit

               -  Individuals who are used acceptable contraceptive methods from 3 month prior to
                  the subject's study entry to 1 month after vaccination (acceptable contraceptive
                  methods; condom, diaphragm or cervical cap)

          2. If male who is sexually active with the female &quot;of childbearing potential&quot; , the
             individuals who agree to use any of the acceptable contraceptive methods during this
             study period and agree to not donate the sperm until 1 month

          3. At screening visits, individuals who are over 55 kg in man, over 50kg in woman and
             whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)

          4. Individual who has no clinically significant abnormalities in screening test within 28
             days prior to vaccination

          5. Individuals who were voluntarily signed informed consent form after receiving
             education about this study and able to comply with the requirements for the study

        Exclusion Criteria:

          1. Individuals who received any other vaccines within 4 weeks prior to the screening
             visit

          2. Individuals who are planning to receive the other vaccines during this study

          3. Individuals who had wound, scar, tattoo, dermatological disorders or injection
             affecting safety evaluation

          4. Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : &gt;5 cups/day,
             alcohol : 210g/week, smoke : 10 /day)

          5. Individuals who received any other investigational product within 90 days prior to
             vaccination

          6. individuals who donated the whole blood within 60 days or apheresis within 30 days
             prior to vaccinating investigational product

          7. Individuals who administered with another prescription medicine, herbal medicine
             within 14 days or over-the-counter drug or vitamins within 7 days before vaccination

          8. Individuals with history or illness affecting immune system (1) individuals with
             continuously anti-viral therapy within 6 months prior to participating in this study
             (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia
             affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary
             or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia,
             dysgammaglobulinemia) (4) Individuals who are receiving immunosuppressive therapy (5)
             Individuals who have treated immunoglobulin or blood-derived products within 6 months
             of enrollment (6) Individuals with a family history of congenital or hereditary
             immunodeficiency

          9. Individuals with any clinically relevant history of other disease or disorder -
             gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome),
             psychiatric or malignant tumor

         10. Individuals with any febrile illness or body temperature ≥38℃ before vaccination

         11. Individuals known hypersensitivity or allergy to components of investigational product
             (including gelatin and neomycin)

         12. Individuals who are any clinically significant abnormality following the
             investigator's review of the pre-study physical examination, ECG, and clinical
             laboratory tests

         13. Pregnancy or breastfeeding

         14. Any other ineligible condition at the discretion of the investigator that would be
             ineligible to participate the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

